BioPorto has finished new protocol for FDA submission
Danish diagnostics player BioPorto has taken an important step toward resubmitting and application to the US FDA for its NGAL kidney test.
BY ELIZABETH MØNSTED JOHANSEN
Diagnostics company BioPorto has moved one step closer to a resubmission of an application for its NGAL test to the US Food and Drug Administration (FDA), which rejected the product last spring.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bioporto makes management change
For abonnenter
